Report top-line results from Phase 2 ADX-629 proof-of-concept trials
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Mar 2021
- Due
- 31 Dec 2021
- Delivered
- March 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Top-line results from the trials are expected by the end of 2021.”
What we found
Evidence strength A What the grades mean
The company reported positive top-line data from Phase 2 proof-of-concept trials of ADX-629 during its Research & Development Day in March 2022, meeting the commitment deadline.
-
A Aldeyra Therapeutics, Inc. 8-K filed 2022-05-05
“At its Research & Development Day in March, Aldeyra reported positive top-line data from Phase 2 proof-of-concept trials of ADX-629” ✓ confirmed on the page
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +546 days
- 4 versions
-
Version 1 · original · stated 11 Mar 2021
Deadline 31 Dec 2021 (“by the end of 2021”) · wording expected
-
Version 2 · stated 17 Mar 2022
Deadline 31 Mar 2022 (“by the end of March 2022”) · wording expected
“Top-Line Data from Proof-of-Concept Clinical Trials of ADX-629 in Multiple Systemic Indications Expected by the End of March 2022”
-
Version 3 · stated 5 Aug 2022
Deadline 31 Dec 2022 (“the second half of this year”) · wording expected
“Aldeyra expects to report top-line results from a Phase 2 clinical trial in acute alcoholic hepatitis”
-
Version 4 · stated 5 Aug 2022
Deadline 30 Jun 2023 (“the first half of 2023”) · wording expected
“Top-line results from the ongoing Phase 2 clinical trial of ADX-629 in chronic cough are anticipated in the first half of 2023.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Top-line results from Phase 2 ADX-629 trials
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ALDX-025638 · Corrections policy